Key Developments: Vexim SA (ALVXM.PA)

ALVXM.PA on Paris Stock Exchange

11.06EUR
7:51am EDT
Price Change (% chg)

€-0.16 (-1.43%)
Prev Close
€11.22
Open
€11.40
Day's High
€11.40
Day's Low
€10.94
Volume
5,575
Avg. Vol
11,666
52-wk High
€12.20
52-wk Low
€9.40

Search Stocks

Latest Key Developments (Source: Significant Developments)

Vexim says SpineJack’s CE Mark expanded to all types of vertebral compression fractures
Tuesday, 8 Apr 2014 11:45am EDT 

Vexim SA:Says it has obtained approval in Europe to extend SpineJack system's indications to all types of vertebral compression fractures.  Full Article

Vexim SA announces results of study into use of Spinejack for vertebral compression factors
Monday, 10 Mar 2014 01:00pm EDT 

Vexim SA:Announces that results of long term retrospective study of 178 patients confirm effectiveness of SpineJack for treating vertebral compression fractures.Vertebral pain was assessed using Visual Analog Scale (VAS) and showed decrease of 75 pct at end of observation period.Functional capacity was measured using Oswestry Disability Index (ODI) and showed improvement of 92 pct at end of evaluation period.Low rate of adjacent vertebral fractures (2.2 pct) was observed.  Full Article

Vexim SA's capital increase oversubscribed up to 11.8 mln euros
Wednesday, 22 Jan 2014 01:24pm EST 

Vexim SA:Says due to the full exercise of the increase option in the company's capital increase, the initial amount of 10 million euros was finally increased to 11.8 million euros, including issue premium.Says it reflects the issuance of 1,242,000 additional new shares.Says that, in accordance with its subscription commitment, Bpifrance Participations has subscribed to the offering for an amount of 5 million euros and becomes a shareholder of the company with 8.9 percent of the share capital.  Full Article

Vexim SA launches 10 million euro capital increase
Thursday, 16 Jan 2014 01:00am EST 

Vexim SA:Announces the launch of a capital increase without preferential subscription rights nor priority subscription period, by issuance of 1,080,000 new shares.Says it aims to raise a gross amount of about 10 million euros.Says the amount of the capital increase may be increased up to a maximum of about 11.5 million euros (1,242,000 shares) in the event of the exercise in full by the Company of its option to increase the issue.Says Bpifrance Participations has committed, subject to conditions, to subscribe to the capital increase for a maximum of 50% of the issued amount and in the limit of 5 million euros.  Full Article

Vexim SA announces launch of Interface
Monday, 9 Dec 2013 11:45am EST 

Vexim SA:Says it is launching Interface, a new biomaterial for bone fixation.Says Interface is a biological alternative to existing orthopedic cements for treating traumatic vertebral fractures.  Full Article

Vexim SA announces results of study of SpineJack
Monday, 2 Dec 2013 11:45am EST 

Vexim SA:Says the results of a new comparative biomechanical study carried out by Marburg University’s Traumatology Department (Germany) have been published in THE SPINE JOURNAL.Says the aim of this new study was to evaluate the anatomic restoration of 24 fractured vertebral bodies with osteoporosis by comparing the SpineJack and balloon kyphoplasty techniques.Says the results once again demonstrated a difference in favor of the SpineJack regarding the restoration of vertebral height that is achieved to reestablish spinal balance.  Full Article

Vexim SA Announces Results of Retrospective Study of SpineJack
Tuesday, 12 Nov 2013 11:45am EST 

Vexim SA announced that the results of a retrospective study of 77 patients confirm the effectiveness of SpineJack for treating vertebral compression fractures. This single-center, retrospective, observational, consecutive study was conducted by Dr. Christian Renaud, an orthopedic surgeon at the Toulouse Lautrec Clinic in Albi (France). The study included 77 patients suffering from vertebral fractures due to trauma or osteoporosis who were followed for up to 5 years after SpineJack implantation. The objective was to assess the risk/benefit ratio for the patient in terms of pain reduction, recovery of functional capacities, and maintenance of vertebral restoration. In this study, 100% of patients experienced a reduction in vertebral pain immediately after surgery and one year later. Vertebral pain was assessed using a Visual Analog Scale (VAS) and showed a statistically decrease of 86% at one year. A publication in Spine showed a 68% decrease for balloon kyphoplasty and 67% for the KIVA device. Functional capacity was measured using the Oswestry Disability Index (ODI). Results showed an improvement of 81% at one year. A publication in Spine reported an improvement of 58% for balloon kyphoplasty and 50% for the KIVA device at one year. The restoration of the spinal balance and the maintenance of this restoration over time are decisive factors in the low rate of adjacent vertebral fractures observed (2.6%).  Full Article

Vexim SA Announces Preliminary Results of International Clinical Study on Performance of SpineJack in Treating Vertebral Fractures
Tuesday, 5 Nov 2013 11:45am EST 

Vexim SA announced that the preliminary results of a study on 103 patients confirm the positive performance of SpineJack in treating vertebral fractures. Height restoration and endplates reconstruction with the SpineJack were demonstrated immediately postoperative and at 3 months, even with a high percentage of very complex fractures. In the severe fractures group, the mean of maximum height restoration is 7.62 mm (scanner imaging measurements). The reported rate of adjacent fractures is 2.9% compared with 11% to 21% for vertebroplasty and kyphoplasty techniques1, thus suggesting a direct link between optimal endplate restoration by SpineJack and a reduction of the risk of further fractures. Vertebral pain was assessed using a Visual Analog Scale (VAS), and showed a post op decrease of 79%. A recent publication in the Spine Journal showed a 68% decrease for balloon kyphoplasty and 67% for the KIVA device. In addition, the decrease in pain allowed a reduction in the consumption of analgesics. Three months after the operation, 98% of patients were using mild analgesics or no medication at all. Functional capacity was measured using the Oswestry Disability Index (ODI). Results showed an improvement of 81% at 3 months. A recent publication2 in the Spine Journal reported a score of 58% for balloon kyphoplasty and 50% for the KIVA device respectively at 1 year.  Full Article

CLINICAL BIOMECHANICS Publishes Study Proving Positive Performance of Vexim SA's SpineJack-DJ
Thursday, 12 Sep 2013 11:45am EDT 

Dow Jones reported that Vexim SA announced that the results of a comparative biomechanical study carried out by Marburg University's Traumatology department (Germany) were published in the August issue of the CLINICAL BIOMECHANICS international journal. The aim of this study was to evaluate the anatomic restoration of 36 fractured vertebral bodies with osteoporosis and the maintaining of the gained height after recompression by comparing the Company's SpineJack and balloon kyphoplasty techniques. The results obtained demonstrate an advantage in favor of the SpineJack regarding the restoration of vertebral height that is carried out to reestablish the spinal column's balance.  Full Article

Vexim SA Announces EUR 2.5 Million Investment by Truffle Capital
Monday, 12 Aug 2013 11:45am EDT 

Vexim SA announced that it decided on August 12, 2013 to increase its share capital by EUR 2.5 million, including share premiums, underwritten by the investment funds managed by Truffle Capital, its historical shareholder. The Board of Directors issued 263,991 new shares on behalf of the Truffle Capital investment funds at a unit price of EUR 9.47, which corresponds to the average share price weighed by volumes over the last five trading days prior to the issue date, and the application of a 5% discount. Following this new share issue and the exercise of warrants “BCE 2007”, the share capital was increased to EUR 459,064.50, divided into 4,590,645 shares with a nominal value of EUR 0.10 per share. Shareholders with a 1% stake will see their shareholdings change to 0.94% of capital on a non-diluted basis.  Full Article

No consensus analysis data available.
Search Stocks